Inspiremd, Inc. (NSPR) Stock Price & Analysis
Inspiremd, Inc. (NSPR) fell 1.64% to USD 0.68 as of July 25, 2026 at 10:42 UTC, according to Nexqual real-time market data.
NSPR last closed at USD 0.69; the session ranged USD 0.68–0.69 on volume of 15,389 shares. Market capitalization is $32.01M, with a 52-week range of USD 0.63–2.93 (NCM). Source: Nexqual, July 25, 2026 at 10:42 UTC.
Key Statistics (as of July 25, 2026 at 10:42 UTC)
| Price | USD 0.68 |
|---|---|
| Change | ▼ 1.64% (down) |
| Previous Close | USD 0.69 |
| Open | USD 0.69 |
| Day Range | USD 0.68 – 0.69 |
| 52-Week Range | USD 0.63 – 2.93 |
| Volume | 15,389 shares |
| Market Cap | $32.01M |
| Exchange | NCM |
Technical Analysis (NSPR)
Nexqual's technical model rates NSPR "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 10:42 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.33 (neutral) |
| vs SMA50 | Below (USD 0.81) |
| MACD | -0.03 (negative) |
Analyst Ratings (NSPR)
Wall Street analysts rate NSPR "None" based on 3 analysts, with a mean price target of USD 3.67 (range USD 3–4), per Nexqual as of July 25, 2026 at 10:42 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 3.67 |
| High Target | USD 4 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (NSPR)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $1.38M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.16 vs est -0.18 ▲ beat |
| 2025-12-31 | USD -0.14 vs est -0.19 ▲ beat |
| 2025-09-30 | USD -0.17 vs est -0.2 ▲ beat |
| 2025-06-30 | USD -0.26 vs est -0.26 ▲ beat |
Source: Nexqual, July 25, 2026 at 10:42 UTC.
Financials & Fundamentals (NSPR)
| Total Revenue | $10.85M |
|---|---|
| Revenue Growth (YoY) | +122.20% |
| Gross Margin | +28.06% |
| Operating Margin | -411.36% |
| Profit Margin | +0.00% |
| ROE | -142.60% |
| Debt / Equity | 7.13 |
| Current Ratio | 5.15 |
| Total Cash | $41.57M |
| Total Debt | $3.11M |
| Free Cash Flow | $-21.12M |
Source: Nexqual, July 25, 2026 at 10:42 UTC.
Financial Health Score (NSPR)
Nexqual rates Inspiremd, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 10:42 UTC.
| Growth | Strong — Revenue +28% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $42M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$21M, burning cash |
| Efficiency | Critical — ROE -143%, ROA -68.5% |
Ownership (NSPR)
| Insider Ownership | +19.83% |
|---|---|
| Institutional Ownership | +48.68% |
| Shares Outstanding | 46.84M |
| Float | 26.29M |
| Short % of Float | +0.17% |
Source: Nexqual, July 25, 2026 at 10:42 UTC.
Leadership (NSPR)
Inspiremd, Inc. is led by Marvin L. Slosman (age 61), President, CEO & Director, per Nexqual as of July 25, 2026 at 10:42 UTC.
| President, CEO & Director | Marvin L. Slosman (age 61) |
|---|---|
| CFO, Secretary & Treasurer | Michael A. Lawless (age 56) |
| Vice President of Human Resources & Organizational Development | Donna DeChant |
Major Backers & Investors (NSPR)
Notable institutional backers of Inspiremd, Inc. include Rosalind Advisors, Inc., Nantahala Capital Management, LLC, Aberdeen Group plc, according to Nexqual as of July 25, 2026 at 10:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rosalind Advisors, Inc. | 8.34% |
| Nantahala Capital Management, LLC | 7.21% |
| Aberdeen Group plc | 6.78% |
| Orbimed Advisors LLC. | 6.69% |
| abrdn Healthcare Investors | 5.47% |
| Parkman Healthcare Partners LLC | 5.16% |
| Velan Capital Investment Management LP | 4.48% |
| Marshall Wace LLP | 3.97% |
Source: Nexqual, July 25, 2026 at 10:42 UTC.
From Inspiremd, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally.
- It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OGEN | Oragenics Inc. | USD 0.51 | ▼ 3.58% |
| MBAI | Check-Cap Ltd. | USD 1.1 | ▲ 8.91% |
| JAGX | Jaguar Health, Inc. | USD 0.96 | ▼ 27.59% |
| ATOS | Atossa Therapeutics, Inc. | USD 2.3 | ▼ 5.56% |
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:42 UTC. This page is informational and not investment advice.